Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
作者： J. E. Romaguera , F. B. Hagemeister , P. McLaughlin , M. A. Rodriguez , C. Bachier
DOI: 10.3109/10428199809059250
关键词:
摘要: A prospective phase II study was carried out in 48 patients with relapsed or refractory non-Hodgkin's lymphoma using paclitaxel 27.5 mg/M2 i.v. by continuous infusion over 24 hours daily on days 1, 2, 3, and 4 combination mitoxantrone 8 day 1 ifosfamide/mesna 1.33 grams/M2 3 (MINT). Responding completed four cycles of MINT were consolidated etoposide, solumedrol [methylprednisolone], high-dose cytarabine [Ara-C], platinum (ESHAP). Forty-eight entered the between 1994 1996 at The University Texas M. D. Anderson Cancer Center. Overall response after first 67% (16% complete [CR]+ 51% partial [PR]) consolidation ESHAP it 49% (26% CR + 23% PR). Variables associated an improved rate better failure-free survival included number prior treatments to treatment. comparison a similar group treated mesna, ifosfamide, mitoxantrone, etoposide (MINE)-ESHAP revealed no major differences outcome.
sci-hub.se 参考文章(14)
F. Cabanillas, F. B. Hagemëister, S. Riggs, P. Salvador, W. Velasquez, P. Mclaughlin, T. Smith, Results of ifosfamide-Etoposide combinations for patients with recurrent or refractory aggressive lymphoma Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. pp. 485- 492 ,(1985) , 10.1007/978-1-4613-2607-6_52
W H Wilson, B A Chabner, G Bryant, S Bates, A Fojo, J Regis, E S Jaffe, S M Steinberg, B R Goldspiel, B D Cheson, Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. Journal of Clinical Oncology. ,vol. 13, pp. 381- 386 ,(1995) , 10.1200/JCO.1995.13.2.381
A Younes, J P Ayoub, F B Hagemeister, P McLaughlin, A Sarris, M A Rodriguez, F Swan, J E Romaguera, J Martin, F Cabanillas, No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. Journal of Clinical Oncology. ,vol. 14, pp. 543- 548 ,(1996) , 10.1200/JCO.1996.14.2.543
M A Rodriguez, F C Cabanillas, W Velasquez, F B Hagemeister, P McLaughlin, F Swan, J E Romaguera, Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology. ,vol. 13, pp. 1734- 1741 ,(1995) , 10.1200/JCO.1995.13.7.1734
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
E. K. Rowinsky, L. A. Cazenave, R. C. Donehower, Taxol: A Novel Investigational Antimicrotubule Agent Journal of the National Cancer Institute. ,vol. 82, pp. 1247- 1259 ,(1990) , 10.1093/JNCI/82.15.1247
ANAS YOUNES, JEAN-PIERRE AYOUB, ANDREAS SARRIS, FREDERICK HAGEMEISTER, LUCILLE NORTH, ODEAL PATE, PETER MCLAUGHLIN, M. ALMA RODRIGUEZ, JORGE ROMAGUERA, RAZELLE KURZROCK, ALEJANDRO PRETI, CARLOS BACHIER, TERRY SMITH, FERNANDO CABANILLAS, Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology. ,vol. 96, pp. 328- 332 ,(1997) , 10.1046/J.1365-2141.1997.D01-2012.X
Harris Nancy Lee, Jaffe Elaine S, Stein Harald, Banks Peter M, Chan John KC, Cleary Michael L, Delsol Georges, De Wolf-Peeters Christine, Falini Brunangelo, Gatter Kevin C, Grogan Thomas M, Isaacson Peter G, Knowles Daniel M, Mason David Y, Muller-Hermelink Hans-Konrad, Pileri Stefano A, Piris Miguel A, Ralfkiaer Elisabeth, Warnke Roger A., A revised European-American classification of lymphoid neoplasms : a proposal from the international lymphoma study group Blood. ,vol. 84, pp. 1361- 1392 ,(1994) , 10.1182/BLOOD.V84.5.1361.1361
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer Journal of the National Cancer Institute. ,vol. 65, pp. 25- 32 ,(1980) , 10.1093/JNCI/65.1.25
W S Velasquez, P McLaughlin, S Tucker, F B Hagemeister, F Swan, M A Rodriguez, J Romaguera, E Rubenstein, F Cabanillas, ESHAP--an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-year Follow-Up Study Journal of Clinical Oncology. ,vol. 12, pp. 1169- 1176 ,(1994) , 10.1200/JCO.1994.12.6.1169